Sugi Predict

Sugi Predict / Compounds / SCHEMBL701485

SCHEMBL701485

SCHEMBL701485

CCC(C#N)(C(=O)O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CYP2C19 P33261 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ CYP1A2 P05177 2/20 0.39
▸ CCR1 P32246 2/20 0.39
▸ CYP2D6 P10635 3/20 0.39
▸ DRD2 P14416 2/20 0.39
▸ OPRM1 P35372 2/20 0.39
▸ DRD3 P35462 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ KIF11 P52732 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ KCNN4 O15554 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7900944 0.90 CYP2C9 (0.47) ALDH1A1MAPTL3MBTL1
SCHEMBL27560876 0.87 MAPT (0.40) ALDH1A1MAPTTSHRCYP2C19HIF1A
SCHEMBL10988395 0.86 MAPT (0.40) ALDH1A1MAPTTSHRCYP2C19HIF1A
SCHEMBL10635869 0.86 MAPT (0.40) ALDH1A1MAPTTSHRCYP2C19HIF1A
SCHEMBL119698 0.86 MAPT (0.47) ALDH1A1MAPTCYP2C19HIF1ACYP1A2
SCHEMBL10636185 0.86 MAPT (0.40) ALDH1A1MAPTTSHRCYP2C19HIF1A
SCHEMBL2277628 0.82 TAS1R3 (0.39) ALDH1A1TSHRCYP1A2KMT2AL3MBTL1
SCHEMBL9214363 0.82 CCR1 (0.50) ALDH1A1MAPTTSHRCYP2C19CYP1A2
SCHEMBL7903133 0.81 CYP2C19 (0.48) ALDH1A1MAPTTSHRCYP2C19HIF1A
SCHEMBL11823794 0.80 ALDH1A1 (0.40) ALDH1A1MAPTTSHRCYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304529-A1 BIOBASED CYANOACRYLATE COMPOUND BOSTIK SA (FR) 2025-10-02 — — US disclosed
EP-4532465-A1 BIOBASED CYANOACRYLATE COMPOUND Bostik SA (FR) 2025-04-09 — — EP disclosed
WO-2023232948-A1 BIOBASED CYANOACRYLATE COMPOUND BOSTIK SA (FR) 2023-12-07 — — WO disclosed
EP-4286369-A1 BIOBASED CYANOACRYLATE COMPOUND Bostik SA (FR) 2023-12-06 — — EP disclosed
CN-113966271-A Agent capable of reacting with or removing oxygen molecules 李蓁蓁 2022-01-21 — — CN disclosed
EP-1688424-B1 PHOSPHONIUM BORATE COMPOUND AND METHOD OF USING THE SAME HOKKO CHEM IND CO (JP) 2016-01-13 — — EP disclosed
EP-2527350-B1 Method for preparing phosphine butadiene ligands, complexes thereof with copper and the use of same in catalysis CENTRE NAT RECH SCIENT (FR) 2015-06-03 — — EP disclosed
US-8877515-B2 Measurement kit and an immunochromatography method FUJIFILM CORPORATION (JP) 2014-11-04 — — US disclosed
US-8835182-B2 Immunochromatographic device FUJIFILM CORPORATION (JP) 2014-09-16 — — US disclosed
US-8604249-B2 Process for producing phosphonium borate compound, novel phosphonium borate compound, and method of using the same HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2013-12-10 — — US disclosed
US-5622983-A ANTIOBESITY AGENTS, ANTIPSYCHOTIC AGENTS, ANTIULCER AGENTS WARNER-LAMBERT COMPANY (US) 1997-04-22 — — US disclosed
US-5580896-A Treatment of pain and colorectal cancer with dipeptoids of α-substituted Trp-Phe derivatives WARNER-LAMBERT COMPANY (US) 1996-12-03 — — US disclosed
US-5281515-A A substrate with silver halide, binder and reducing agent and merocyanine sensitizer MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-01-25 — — US disclosed
US-5278316-A Indoles WARNER-LAMBERT COMPANY (US) 1994-01-11 — — US disclosed
EP-0559228-A1 Photothermographic elements MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1993-09-08 — — EP disclosed
EP-0533007-A1 Thermally developable photographic elements MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1993-03-24 — — EP disclosed
EP-0479910-A1 N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED Trp-Phe- AND PHENETHYLAMINE DERIVATIVES WARNER-LAMBERT COMPANY (US) 1992-04-15 — — EP disclosed
WO-1991000274-A1 N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED TRP-PHE- AND PHENETHYLAMINE DERIVATIVES WARNER-LAMBERT COMPANY (US) 1991-01-10 — — WO disclosed
EP-0405537-A1 N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives WARNER-LAMBERT COMPANY (US) 1991-01-02 — — EP disclosed
US-4740228-A Plant growth regulating compounds and compositions and a process for the preparation thereof EGYT GYOGYSZERVEGYESZETI GYAR (HU) 1988-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304529-A1 BIOBASED CYANOACRYLATE COMPOUND BAP1, CBR1, CBR3 ALDH1A1 95/4885MAPT 2673/4885TSHR 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.